Literature DB >> 15634724

Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH Deficiency: analysis of data from KIGS.

Michael B Ranke1, Anders Lindberg, Kerstin Albertsson-Wikland, Patrick Wilton, David A Price, Edward O Reiter.   

Abstract

In children, GH secretion and sensitivity to GH are influenced by developmental changes. It is not clear whether the response to GH in very young children with GH deficiency (GHD) is the same as that in older, prepubertal children. A cohort of 265 children (180 males and 85 females) with idiopathic GHD from KIGS (Pfizer International Growth Database), with treatment started at less than 3 yr of age (mean age, 1.9 yr; group I) was compared with a cohort of 509 children (331 males and 178 females; group II) with treatment started at 7-8 yr of age (mean age, 7.5 yr). The following differences (P < 0.01) were found (given in mean values) between groups I and II at the start of GH treatment: 9% vs. 5% breech delivery, 38% vs. 14% multiple pituitary hormone deficiency, 4.2 vs. 5.9 ng/ml maximum GH in response to tests, -0.1 vs. -0.8 midparental height (MPH) sd score (SDS), -3.1 vs. -2.5 height SDS, 0.83 vs. 0.66 IU/kg.wk GH dose. After the first year of GH, the results were: 13.3 vs. 8.6 cm/yr height velocity, and 1.7 vs. 0.6 maximum change in height SDS. Using the previously developed growth prediction models for prepubertal children with idiopathic GHD more than 2 yr of age, our analysis revealed differences in the indexes of responsiveness in prediction models (Studentized residuals SDS, 0.7 vs.-0.3) and strikingly higher responsiveness to treatment among the young cohort, but with large scatter. Thus, new prediction models of height velocity (centimeters per year) were derived by means of multiple regression analysis for the young cohort, either involving (model A) or excluding (model B) the GH peak in tests. Model A explained 54% of the total variability with an error sd of 2.1 cm. Height velocity correlated with (parameters in order of importance) age (-), maximum GH (-), GH dose (+), weight SDS (+), height SDS minus MPH SDS (-), and birth weight SDS (+). Model B explained 45% of the total variability with an error sd of 2.3 cm. Height velocity correlated with (parameters in order of importance) age (-), GH dose (+), birth weight SDS (+), height SDS minus MPH SDS (-), and weight SDS (+). The predictors were qualitatively the same as those in the total prepubertal model involving all children more than 2 yr of age, but their quantitative impact in terms of partial contribution and the order of their importance were different for the young cohort. In particular, the partial contribution of the GH dose was higher, suggesting a greater gain in height per GH dose unit in the very young than in the older children. However, the rank order of the GH dose in the new models was lower, which suggests a slightly low sensitivity to GH in toddlers after the phase of severe GH insensitivity during early infancy. The early detection and GH treatment of congenital GHD is advantageous as a cost-effective strategy for achieving greater improvement of absolute height and growth velocity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15634724     DOI: 10.1210/jc.2004-1051

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.

Authors:  Wayne V Moore; Huong Jil Nguyen; Gad B Kletter; Bradley S Miller; Douglas Rogers; David Ng; Jerome A Moore; Eric Humphriss; Jeffrey L Cleland; George M Bright
Journal:  J Clin Endocrinol Metab       Date:  2015-12-16       Impact factor: 5.958

2.  Implications of a data-driven approach to treatment with growth hormone in children with growth hormone deficiency and Turner syndrome.

Authors:  Stefan Kaspers; Michael B Ranke; Donald Han; Jane Loftus; Hartmut Wollmann; Anders Lindberg; Mathieu Roelants; Joris Kleintjens
Journal:  Appl Health Econ Health Policy       Date:  2013-06       Impact factor: 2.561

3.  Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.

Authors:  Ling Hou; Zhi-Hang Chen; Dong Liu; Yuan-Guo Cheng; Xiao-Ping Luo
Journal:  Drug Des Devel Ther       Date:  2015-12-18       Impact factor: 4.162

Review 4.  Possible effects of an early diagnosis and treatment in patients with growth hormone deficiency: the state of art.

Authors:  Stefano Stagi; Perla Scalini; Giovanni Farello; Alberto Verrotti
Journal:  Ital J Pediatr       Date:  2017-09-16       Impact factor: 2.638

5.  Final Height in Children with Idiopathic Growth Hormone Deficiency treated with Growth Hormone: Albanian experience.

Authors:  A Gjikopulli; L Grimci; L Kollçaku; S Tomori; P Cullufi; P Hoxha; Z Ylli
Journal:  Curr Health Sci J       Date:  2015-03-15

6.  Criteria for First-Year Growth Response to Growth Hormone Treatment in Prepubertal Children With Growth Hormone Deficiency: Do They Predict Poor Adult Height Outcome?

Authors:  Saartje Straetemans; Jean De Schepper; Muriel Thomas; Sylvie Tenoutasse; Véronique Beauloye; Raoul Rooman
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-26       Impact factor: 5.555

7.  Poor growth response during the first year of growth hormone treatment in short prepubertal children with growth hormone deficiency and born small for gestational age: a comparison of different criteria.

Authors:  Raoul Rooman; Jean De Schepper; Saartje Straetemans; Muriel Thomas; Margarita Craen
Journal:  Int J Pediatr Endocrinol       Date:  2018-10-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.